Management and treatment of glycogenosis type II

被引:41
作者
Bembi, B. [2 ]
Cerini, E. [3 ]
Danesino, C. [1 ]
Donati, M. A. [4 ]
Gasperini, S. [4 ]
Morandi, L.
Musumeci, O. [5 ]
Parenti, G. [6 ,9 ]
Ravaglia, S. [7 ]
Seidita, F.
Toscano, A. [5 ]
Vianello, A. [8 ]
机构
[1] Univ Pavia, IRCCS San Matteo, I-27100 Pavia, Italy
[2] Univ Hosp Santa Maria Misericordia Udine, Reg Coordinat Ctr Rare Dis, Udine, Italy
[3] Hosp Mantua, Dept Neonatal Pathol, Mantau, Italy
[4] Meyer Childrens Hosp, Metab & Muscular Unit, Florence, Italy
[5] Univ Messina, Dept Neurosci, Messina, Italy
[6] Univ Naples Federico II, Dept Pediat, Naples, Italy
[7] Univ Pavia, Neurol Inst C Mondino, Dept Neurol Sci, I-27100 Pavia, Italy
[8] Univ City Hosp Padova, Resp Pathophysiol Unit, Padua, Italy
[9] Univ Naples Federico II, Telethon Inst Genet & Med, Naples, Italy
关键词
D O I
10.1212/WNL.0b013e31818da93f
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glycogenosis type II is a multisystem disorder that requires management by a multidisciplinary team. The team should include several specialists, such as a metabolic disease specialist or biochemical geneticist, cardiologist, pulmonologist, neurologist, neuromuscular specialist, intensivist, orthopedist, respiratory therapist, physical therapist, occupational therapist, otolaryngologist speech therapist, audiologist, genetic counselor, and a metabolic dietician, who, as a team, will be capable of addressing the different manifestations of the condition. Aspects of functional assessment, rehabilitation, nutritional management, care coordination, nursing, genetic counseling, prenatal diagnosis, and screening are discussed in this article. In addition, treatment of glycogenosis type II is reviewed with attention to emerging therapeutic options. NEUROLOGY 2008; 71(Suppl 2): S12-S36
引用
收藏
页码:S12 / S36
页数:25
相关论文
共 142 条
[51]   Fatigue: an important feature of late-onset Pompe disease [J].
Hagemans, Marloes L. C. ;
van Schie, Sabine P. M. ;
Janssens, A. Cecile J. W. ;
Van Doorn, Pieter A. ;
Reuser, Arnold J. J. ;
van der Ploeg, Ans T. .
JOURNAL OF NEUROLOGY, 2007, 254 (07) :941-945
[52]   Course of disability and respiratory function in untreated late-onset Pompe disease [J].
Hagemans, MLC ;
Hop, WJC ;
Van Doorn, PA ;
Reuser, AJJ ;
van der Ploeg, AT .
NEUROLOGY, 2006, 66 (04) :581-583
[53]   Disease severity in children and adults with Pompe disease related to age and disease duration [J].
Hagemans, MLC ;
Winkel, LPF ;
Hop, WCJ ;
Reuser, AJJ ;
Van Doorn, PA ;
Van der Ploeg, AT .
NEUROLOGY, 2005, 64 (12) :2139-2141
[54]   Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients [J].
Hagemans, MLC ;
Winkel, LPF ;
Van Doorn, PA ;
Hop, WJC ;
Loonen, MCB ;
Reuser, AJJ ;
Van der Ploeg, AT .
BRAIN, 2005, 128 :671-677
[55]   Late-onset Pompe disease primarily affects quality of life in physical health domains [J].
Hagemans, MLC ;
Janssens, ACJW ;
Winkel, LPF ;
Sieradzan, KA ;
Reuser, AJJ ;
Van Doorn, PA ;
Van der Ploeg, AT .
NEUROLOGY, 2004, 63 (09) :1688-1692
[56]   Twenty-two novel mutations in the lysosomal α-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II [J].
Hermans, MMP ;
van Leenen, D ;
Kroos, MA ;
Beesley, CE ;
Van der Ploeg, AT ;
Sakuraba, H ;
Wevers, R ;
Kleijer, W ;
Michelakakis, H ;
Kirk, ER ;
Fletcher, J ;
Bosshard, N ;
Basel-Vanagaite, L ;
Besley, G ;
Reuser, AJJ .
HUMAN MUTATION, 2004, 23 (01) :47-56
[57]   Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II [J].
Hesselink, RP ;
Wagenmakers, AJM ;
Drost, MR ;
Van der Vusse, GJ .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2003, 1637 (02) :164-170
[58]   Impaired performance of skeletal muscle in α-glucosidase knockout mice [J].
Hesselink, RP ;
Gorselink, M ;
Schaart, G ;
Wagenmakers, AJM ;
Kamphoven, J ;
Reuser, AJJ ;
van der Vusse, GJ ;
Drost, MR .
MUSCLE & NERVE, 2002, 25 (06) :873-883
[59]  
Hirschhorn R., 2001, METABOLIC MOL BASES, P3389
[60]  
HOWARD RS, 1993, Q J MED, V86, P175